The deal provides non-dilutive funding and a path to commercial reach in Asia-Pacific, but all payments are contingent on clinical success and regulatory approval. Monitor the Phase 3 topline data readout in Q1 2027 as the next major catalyst.
Drug in focus
OCGN drug pipeline →OCU400
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- Potential FDA approval in 2027-2028 if Phase 3 succeeds and BLA submission (targeted Q3 2026 rolling) is accepted.
- Next catalyst
- None dated
What to watchWatch for the rolling BLA submission in Q3 2026 as a validation event and the Phase 3 topline readout in Q1 2027 as the primary binary catalyst. The stock has strong institutional accumulation and analyst support (9 Buy, mean PT ~$11.43 vs ~$1.43), but remains pre-revenue with high dilution risk from $130M convertible notes. The Phase 1/2 data was encouraging, durability and a gene-agnostic approach differentiate OCU400 from the only approved therapy, Luxturna.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $0.9500entry
- T+1 · 6d ago +1.09%α −0.22% · $0.9604
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Ocugen entered into an exclusive license agreement with Celairis Therapeutics for OCU400, a modifier gene therapy for retinitis pigmentosa, in Australia, New Zealand, and ASEAN markets. Ocugen receives up to $7.1 million in upfront and milestone payments, a high single-digit royalty on net sales, and 50% of gross profits from the territory. The deal expands Ocugen's global access strategy for OCU400 ahead of Phase 3 topline data expected in Q1 2027.
Key Financial Metrics
Key Facts
- Ocugen granted Celairis an exclusive license to commercialize OCU400 in Australia, New Zealand, and ASEAN markets.
- Ocugen receives up to $7.1 million in upfront and milestone payments, including $6.1 million tied to positive Phase 3 topline results and an upfront fee.
- A $1.0 million milestone is payable upon Australian TGA approval of OCU400.
- Ocugen receives a high single-digit percentage royalty on net sales and 50% of gross profits from OCU400 net sales in the territory.
- Ocugen retains sole right to manufacture OCU400 in the territory; a supply agreement is expected within 90 days.
- Phase 3 LiMeliGhT trial topline data for OCU400 is expected in Q1 2027.
- This is Ocugen's third strategic regional partnership for OCU400.
Financial Impact
Up to $7.1 million in upfront and milestone payments, plus high single-digit royalty on net sales and 50% of gross profits from the territory.
Risk Factors
- All milestone payments depend on positive Phase 3 results and regulatory approvals, which are uncertain.
- OCU400 has not been approved in any jurisdiction; the territory license has no value if the drug fails to gain approval.
- The supply agreement is not yet finalized and may not be entered into.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-124836 |
| Document: tm2629434d1_ex99-1.htm | 0001104659-26-124836 |
| Document: 0001104659-26-124836-index-headers.html | 0001104659-26-124836 |
| Document: 0001104659-26-124836-index.html | 0001104659-26-124836 |
| Document: 0001104659-26-124836.txt | 0001104659-26-124836 |
Track record
23 reports on OCGN
3 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +20.49% at T+20 after the Jun 11, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 10, 20266d ago 8-K Neutral 4/10 Viewing Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
- Nov 6, 202610d ago DEFA14A Neutral 2/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
- Nov 6, 202610d ago DEFA14A Neutral 3/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $0.8745 to $0.8165 Now $0.7730 −11.61% ▼ −6.63% −2.22% vs SPY
- Oct 15, 20264w ago 8-K Neutral 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
- Oct 14, 20264w ago 8-K Mixed 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
- Oct 9, 20265w ago 144 Neutral 2/10 Entry $0.9472 to $0.8854 Now $0.7730 −18.39% ▼ −6.52% −6.51% vs SPY
- Sep 1, 202610w ago Press Release Bullish 7/10 Entry $1.33 to $1.32 Now $0.7730 −41.88% ▼ −0.75% −1.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers